Literature DB >> 24190484

Remifentanil preconditioning alleviating brain damage of cerebral ischemia reperfusion rats by regulating the JNK signal pathway and TNF-α/TNFR1 signal pathway.

Yan Zhang1, Yan-Wei Li, Ya-Xin Wang, Hong-Tao Zhang, Xiao-Mei Zhang, Yu Liang, Xiu-Shan Zhang, Wen-Sheng Wang, Hai-Gen Liu, Yi Zhang, Ling Zhang, Yu-Hua Zheng.   

Abstract

Tumor necrosis factor (TNF) and the TNF receptor (TNFR) superfamily play very important roles for cell death as well as normal immune regulation. Previous studies have strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. The purpose of this investigation was to examine the protective effect of remifentanil preconditioning in cerebral ischemia/reperfusion injury (CIR) and its possible molecular mechanism. Results showed that Remifentanil pretreatment significantly decreased the CD4(+) and increased the CD8(+) in cerebral tissues. Additionally, CD4(+)/CD8(+) in CIR + Remifentanil group was markedly lower than that in CIR group. TNF-α and TNFR1 in CIR + Remifentanil group rats was found to be significant lower than that in CIR group rats. The expression levels of Cyt-c, caspase-3, caspase-9 and pJNK proteins in brain of CIR + Remifentanil group rats were found to significantly decreased compared to CIR group rats. In addition, decreased ROS level indirectly inhibit JNK activation and cell death in CIR rat receiving Remifentanil preconditioning. From current experiment results, at least two signal pathways involve into the process of Remifentanil preconditioning inhibiting cerebral damage induced by ischemia reperfusion. The inhibitory effects of Remifentanil preconditioning on the brain damage are achieved probably through blocking the activation of TNF-α/TNFR1, JNK signal transduction pathways, which implies that Remifentanil preconditioning may be a potential and effective way for prevention of the ischemic/reperfusion injury through the suppression extrinsic apoptotic signal pathway induced by TNF-α/TNFR1, JNK signal pathways. Taken together, this study indicated that regulation of the TNF-α/TNFR1 and JNK signal pathways may provide a new therapy for cerebral damage induced by ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190484     DOI: 10.1007/s11033-013-2819-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  66 in total

Review 1.  Programmed cell death: alive and well in the new millennium.

Authors:  S H Kaufmann; M O Hengartner
Journal:  Trends Cell Biol       Date:  2001-12       Impact factor: 20.808

2.  Biochemical evaluation of focal non-reperfusion cerebral ischemia by middle cerebral artery occlusion in rats.

Authors:  Benedicto Oscar Colli; Daniela Pretti da Cunha Tirapelli; Carlos Gilberto Carlotti; Luiza da Silva Lopes; Luis Fernando Tirapelli
Journal:  Arq Neuropsiquiatr       Date:  2008-09       Impact factor: 1.420

3.  Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

Authors:  X Liu; C N Kim; J Yang; R Jemmerson; X Wang
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

4.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

5.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c.

Authors:  T Rossé; R Olivier; L Monney; M Rager; S Conus; I Fellay; B Jansen; C Borner
Journal:  Nature       Date:  1998-01-29       Impact factor: 49.962

Review 6.  Dual role of tumor necrosis factor alpha in brain injury.

Authors:  E Shohami; I Ginis; J M Hallenbeck
Journal:  Cytokine Growth Factor Rev       Date:  1999-06       Impact factor: 7.638

Review 7.  Opioids and cardioprotection.

Authors:  J E Schultz; G J Gross
Journal:  Pharmacol Ther       Date:  2001-02       Impact factor: 12.310

Review 8.  Porcine peripheral blood CD4+/CD8+ dual expressing T-cells.

Authors:  M D Pescovitz; A G Sakopoulos; J A Gaddy; R J Husmann; F A Zuckermann
Journal:  Vet Immunol Immunopathol       Date:  1994-10       Impact factor: 2.046

9.  JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells.

Authors:  Penny Clarke; Suzanne M Meintzer; Yibing Wang; Lisa A Moffitt; Sarah M Richardson-Burns; Gary L Johnson; Kenneth L Tyler
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis.

Authors:  Luca Scorrano; Scott A Oakes; Joseph T Opferman; Emily H Cheng; Mia D Sorcinelli; Tullio Pozzan; Stanley J Korsmeyer
Journal:  Science       Date:  2003-03-06       Impact factor: 47.728

View more
  10 in total

1.  Time-dependent variation of pathways and networks in a 24-hour window after cerebral ischemia-reperfusion injury.

Authors:  Li-Ying Wang; Jun Liu; Yuan Li; Bing Li; Ying-Ying Zhang; Zhi-Wei Jing; Ya-Nan Yu; Hai-Xia Li; Shan-Shan Guo; Yi-Jun Zhao; Zhong Wang; Yong-Yan Wang
Journal:  BMC Syst Biol       Date:  2015-02-27

2.  Neuroprotective effect of pretreatment with ganoderma lucidum in cerebral ischemia/reperfusion injury in rat hippocampus.

Authors:  Wangxin Zhang; Quiling Zhang; Wen Deng; Yalu Li; Guoqing Xing; Xinjun Shi; Yifeng Du
Journal:  Neural Regen Res       Date:  2014-08-01       Impact factor: 5.135

3.  Treatment of surgical brain injury by immune tolerance induced by intrathymic and hepatic portal vein injection of brain antigens.

Authors:  Weijian Yang; Yong Liu; Baolong Liu; Huajun Tan; Hao Lu; Hong Wang; Hua Yan
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

4.  Indispensable role of β-arrestin2 in the protection of remifentanil preconditioning against hepatic ischemic reperfusion injury.

Authors:  Yuting Yang; Caiyang Chen; Cui Cui; Yingfu Jiao; Peiying Li; Ling Zhu; Weifeng Yu; Qiang Xia; Daxiang Wen; Liqun Yang
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

5.  Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice.

Authors:  Clément Chollat; Maryline Lecointre; Matthieu Leuillier; Isabelle Remy-Jouet; Jean-Claude Do Rego; Lénaïg Abily-Donval; Yasmina Ramdani; Vincent Richard; Patricia Compagnon; Bertrand Dureuil; Stéphane Marret; Bruno José Gonzalez; Sylvie Jégou; Fabien Tourrel
Journal:  Front Neurol       Date:  2019-04-24       Impact factor: 4.003

6.  Pre-administration of remifentanil in target-controlled propofol and remifentanil anesthesia prolongs anesthesia induction in neurosurgical patients: A double-blind randomized controlled trial.

Authors:  Jin Hee Ahn; Doyeon Kim; Ik Soo Chung; Jeong Jin Lee; Eun Kyung Lee; Ji Seon Jeong
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 7.  Opioids Preconditioning Upon Renal Function and Ischemia-Reperfusion Injury: A Narrative Review.

Authors:  Julio Palomino; Raquel Echavarria; Adriana Franco-Acevedo; Bibiana Moreno-Carranza; Zesergio Melo
Journal:  Medicina (Kaunas)       Date:  2019-08-23       Impact factor: 2.430

8.  Treatment of Surgical Brain Injury by Immune Tolerance Induced by Peripheral Intravenous Injection of Biotargeting Nanoparticles Loaded With Brain Antigens.

Authors:  Zhen Tian; Lixia Xu; Qian Chen; Ruoyang Feng; Hao Lu; Huajun Tan; Jianming Kang; Yinsong Wang; Hua Yan
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

9.  Effects of remifentanil with or without midazolam pretreatment on the 95% effective dose of propofol for loss of consciousness during induction: A randomized, clinical trial.

Authors:  Jae Chul Koh; Juyeon Park; Na Young Kim; Ann Hee You; Seo Hee Ko; Dong Woo Han
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 10.  Immune Tolerance Therapy: A New Method for Treatment of Traumatic Brain Injury.

Authors:  Ruo-Yang Feng; Qian Chen; Wei-Jian Yang; Xiao-Guang Tong; Zhi-Ming Sun; Hua Yan
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.